AR112834A1 - Derivados de rapamicina - Google Patents
Derivados de rapamicinaInfo
- Publication number
- AR112834A1 AR112834A1 ARP180102741A ARP180102741A AR112834A1 AR 112834 A1 AR112834 A1 AR 112834A1 AR P180102741 A ARP180102741 A AR P180102741A AR P180102741 A ARP180102741 A AR P180102741A AR 112834 A1 AR112834 A1 AR 112834A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkyl
- hydrogen
- group
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
Abstract
La divulgación se refiere a compuestos y sales farmacéuticamente aceptables, y composiciones de los mismos. También se proporcionan métodos para preparar los compuestos y métodos que implican los compuestos o composiciones para tratar trastornos y enfermedades descritos en este documento. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ se selecciona a partir del grupo que consta de hidroxilo, o un compuesto del grupo de fórmulas (2); y R² se selecciona del grupo que consiste en los compuestos del grupo de fórmulas (3) en donde m es 0, 1, 2 ó 3; n es 1, 2 ó 3; o es 1, 2, 3, 4, 5 ó 6; p es 1, 2, 3, 4 ó 5; q es 1, 2, 3, 4 ó 5, en donde la suma de p y q es 2, 3, 4, 5 ó 6; r es 2, 3 ó 4; s es 2, 3 ó 4, en donde la suma de r y s es 4, 5 ó 6; X es O, S, NR⁶ o SO₂; R³ es hidrógeno, alquilo C₁₋₄, hidroxialquilo C₁₋₈, cicloalquilo C₃₋₈alquilo C₀₋₆ o fenilalquilo C₀₋₆; R⁴ es hidrógeno; R⁵ es hidrógeno, hidroxi o ciano; o R⁴ y R⁵ juntos forman =O; y R⁶ es hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₈alquilo C₀₋₆, fenilalquilo C₀₋₆, alquilo C₁₋₆-CO-, cicloalquilo C₃₋₈alquilo C₀₋₆-CO-, alquilo C₁₋₆-SO₂- o cicloalquilo C₃₋₈alquilo C₀₋₆-SO₂-.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563312P | 2017-09-26 | 2017-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112834A1 true AR112834A1 (es) | 2019-12-18 |
Family
ID=63857991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102741A AR112834A1 (es) | 2017-09-26 | 2018-09-24 | Derivados de rapamicina |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10800793B2 (es) |
| EP (2) | EP3687999B1 (es) |
| JP (2) | JP7387590B2 (es) |
| KR (2) | KR102794731B1 (es) |
| CN (2) | CN111094299B (es) |
| AR (1) | AR112834A1 (es) |
| AU (1) | AU2018342784B2 (es) |
| BR (1) | BR112020005898A2 (es) |
| CA (1) | CA3078191A1 (es) |
| DK (1) | DK3687999T3 (es) |
| ES (1) | ES2973975T3 (es) |
| FI (1) | FI3687999T3 (es) |
| HR (1) | HRP20240199T8 (es) |
| HU (1) | HUE065692T2 (es) |
| LT (1) | LT3687999T (es) |
| MX (2) | MX2020007265A (es) |
| PL (1) | PL3687999T3 (es) |
| PT (1) | PT3687999T (es) |
| RS (1) | RS65270B1 (es) |
| SI (1) | SI3687999T1 (es) |
| TW (1) | TW201920189A (es) |
| UY (1) | UY37900A (es) |
| WO (1) | WO2019064182A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| CA3013650A1 (en) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| CN108697729B (zh) | 2016-02-04 | 2023-05-09 | 约翰霍普金斯大学 | 新型GLUT抑制剂rapaglutin及其用途 |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| MX2020011565A (es) | 2018-05-01 | 2021-01-29 | Revolution Medicines Inc | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor. |
| IL312291A (en) | 2018-05-01 | 2024-06-01 | Revolution Medicines Inc | C-26-linked rapamycin analogs as MTOR inhibitors |
| LT3813946T (lt) | 2018-06-15 | 2024-07-10 | Janssen Pharmaceutica Nv | Rapamicino analogai ir jų panaudojimas |
| BR112021011325A2 (pt) | 2018-12-18 | 2021-11-16 | Novartis Ag | Derivados de rapamicina |
| KR102705165B1 (ko) | 2019-01-22 | 2024-09-11 | 에오비안 파마슈티컬스, 인크. | Mtorc 조절제 및 이의 용도 |
| WO2020194209A1 (en) * | 2019-03-26 | 2020-10-01 | Novartis Ag | Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof |
| KR102497821B1 (ko) * | 2019-08-23 | 2023-02-08 | 이화여자대학교 산학협력단 | 신규 mTOR 억제제 화합물 및 이의 용도 |
| KR102486721B1 (ko) * | 2019-08-23 | 2023-01-10 | 이화여자대학교 산학협력단 | 신규 mTOR 억제제 화합물 및 이의 용도 |
| TW202126323A (zh) * | 2019-10-01 | 2021-07-16 | 約翰斯赫普金斯大學 | 雷帕弗辛（Ｒａｐａｆｕｃｉｎ）衍生化合物及其使用方法 |
| CN115209897A (zh) | 2019-12-05 | 2022-10-18 | 安纳库利亚治疗公司 | 雷帕霉素类似物及其用途 |
| DE102020203224A1 (de) | 2020-03-12 | 2021-09-16 | Heinrich-Heine-Universität Düsseldorf | Inhibition von FKBP1A zur Therapie des Triple-negativen Mammakarzinoms |
| US20230133761A1 (en) | 2020-03-12 | 2023-05-04 | Heinrich-Heine-Universität Düsseldorf | Inhibition of fkbp1a for the treatment of triple-negative mammary carcinoma |
| KR102805250B1 (ko) * | 2020-03-27 | 2025-05-08 | 에오비안 파마슈티컬스, 인크. | Mtorc1 조절제 및 이의 용도 |
| CN116322677B (zh) * | 2020-07-21 | 2025-09-23 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| TW202206093A (zh) * | 2020-08-12 | 2022-02-16 | 中國醫藥大學 | Ｓｅｍａ３ｄ拮抗劑用於預防或治療神經退化性疾病以及延長壽命之用途 |
| JP2025522296A (ja) | 2022-05-25 | 2025-07-15 | レヴォリューション・メディスンズ，インコーポレイテッド | ｍＴＯＲ阻害剤によりがんを処置する方法 |
| CN121127477A (zh) * | 2023-04-07 | 2025-12-12 | 瑞泽恩制药公司 | 选择性雷帕霉素类似物及其用途 |
| WO2024243449A1 (en) * | 2023-05-23 | 2024-11-28 | Tornado Therapeutics, Inc. | Rapamycin derivatives and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| ATE404663T1 (de) | 1995-06-07 | 2008-08-15 | Ariad Gene Therapeutics Inc | Auf rapamycin basierende regulation biologischer vorgänge |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| CZ292233B6 (cs) * | 1995-06-09 | 2003-08-13 | Novartis Ag | Deriváty rapamycinu a jejich použití jako léčiv |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| JP2002514165A (ja) | 1996-07-12 | 2002-05-14 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 病原性真菌感染の治療または予防材料および方法 |
| CA2318402A1 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
| EP1363627A2 (en) | 2001-02-19 | 2003-11-26 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| GB0601406D0 (en) | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| US20100081681A1 (en) | 2006-08-16 | 2010-04-01 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| GB0911888D0 (en) * | 2009-07-08 | 2009-08-19 | Oxford Biodynamics Ltd | Method of treating age related disorders |
| WO2011123524A2 (en) * | 2010-03-31 | 2011-10-06 | Auspex Pharmaceutical, Inc. | Macrolide inhibitors of mtor |
| US8906374B2 (en) | 2010-04-20 | 2014-12-09 | Cedars-Sinai Medical Center | Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors |
| EP2670758B1 (en) | 2011-02-04 | 2022-09-28 | Synthon BV | Process for making trisubstituted silyloxyethyl triflates |
| WO2012110953A1 (en) | 2011-02-16 | 2012-08-23 | Novartis Ag | Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| PH12017500997A1 (en) * | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3109250A1 (en) | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Method for the synthesis of rapamycin derivatives |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| KR20200012876A (ko) | 2017-05-02 | 2020-02-05 | 레볼루션 메디슨즈, 인크. | mTOR 억제제로서의 파라마이신 유사체 |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| BR112021011325A2 (pt) | 2018-12-18 | 2021-11-16 | Novartis Ag | Derivados de rapamicina |
| WO2020194209A1 (en) | 2019-03-26 | 2020-10-01 | Novartis Ag | Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof |
-
2018
- 2018-09-24 AR ARP180102741A patent/AR112834A1/es unknown
- 2018-09-24 UY UY0001037900A patent/UY37900A/es not_active Application Discontinuation
- 2018-09-25 HR HRP20240199TT patent/HRP20240199T8/hr unknown
- 2018-09-25 HU HUE18786408A patent/HUE065692T2/hu unknown
- 2018-09-25 TW TW107133541A patent/TW201920189A/zh unknown
- 2018-09-25 EP EP18786408.7A patent/EP3687999B1/en active Active
- 2018-09-25 JP JP2020516599A patent/JP7387590B2/ja active Active
- 2018-09-25 EP EP24150040.4A patent/EP4365179A3/en active Pending
- 2018-09-25 KR KR1020207007749A patent/KR102794731B1/ko active Active
- 2018-09-25 MX MX2020007265A patent/MX2020007265A/es unknown
- 2018-09-25 BR BR112020005898-0A patent/BR112020005898A2/pt unknown
- 2018-09-25 SI SI201831063T patent/SI3687999T1/sl unknown
- 2018-09-25 US US16/141,856 patent/US10800793B2/en active Active
- 2018-09-25 WO PCT/IB2018/057422 patent/WO2019064182A1/en not_active Ceased
- 2018-09-25 PT PT187864087T patent/PT3687999T/pt unknown
- 2018-09-25 ES ES18786408T patent/ES2973975T3/es active Active
- 2018-09-25 PL PL18786408.7T patent/PL3687999T3/pl unknown
- 2018-09-25 CN CN201880057805.6A patent/CN111094299B/zh active Active
- 2018-09-25 CN CN202311329093.8A patent/CN117417351A/zh active Pending
- 2018-09-25 CA CA3078191A patent/CA3078191A1/en active Pending
- 2018-09-25 LT LTEPPCT/IB2018/057422T patent/LT3687999T/lt unknown
- 2018-09-25 FI FIEP18786408.7T patent/FI3687999T3/fi active
- 2018-09-25 RS RS20240184A patent/RS65270B1/sr unknown
- 2018-09-25 AU AU2018342784A patent/AU2018342784B2/en active Active
- 2018-09-25 KR KR1020257011373A patent/KR20250054121A/ko active Pending
- 2018-09-25 DK DK18786408.7T patent/DK3687999T3/da active
-
2020
- 2020-07-13 MX MX2023001876A patent/MX2023001876A/es unknown
- 2020-08-27 US US17/004,434 patent/US20200392159A1/en not_active Abandoned
-
2021
- 2021-10-12 US US17/499,433 patent/US12091424B2/en active Active
-
2023
- 2023-05-18 JP JP2023081938A patent/JP7699626B2/ja active Active
-
2024
- 2024-08-09 US US18/799,328 patent/US20250223297A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112834A1 (es) | Derivados de rapamicina | |
| AR120109A1 (es) | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores | |
| AR121044A1 (es) | Inhibidores de egfr | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| AR109349A1 (es) | Compuestos y usos | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| AR103828A1 (es) | INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b | |
| AR069798A1 (es) | Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa. | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR123078A1 (es) | Medicamentos antiplaquetarios y usos de estos | |
| AR094272A1 (es) | Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| AR104512A1 (es) | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |